AU2001290315A1 - Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding - Google Patents

Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding

Info

Publication number
AU2001290315A1
AU2001290315A1 AU2001290315A AU9031501A AU2001290315A1 AU 2001290315 A1 AU2001290315 A1 AU 2001290315A1 AU 2001290315 A AU2001290315 A AU 2001290315A AU 9031501 A AU9031501 A AU 9031501A AU 2001290315 A1 AU2001290315 A1 AU 2001290315A1
Authority
AU
Australia
Prior art keywords
inhibiting
effect
monoclonal antibody
tlr binding
tlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290315A
Inventor
Shoji Furusako
Sadao Mori
Kamon Shirakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of AU2001290315A1 publication Critical patent/AU2001290315A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001290315A 2000-11-22 2001-09-28 Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding Abandoned AU2001290315A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-356719 2000-11-22
JP2000356719 2000-11-22
PCT/JP2001/008563 WO2002042333A1 (en) 2000-11-22 2001-09-28 Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding

Publications (1)

Publication Number Publication Date
AU2001290315A1 true AU2001290315A1 (en) 2002-06-03

Family

ID=18828903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290315A Abandoned AU2001290315A1 (en) 2000-11-22 2001-09-28 Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding

Country Status (6)

Country Link
US (1) US7264967B2 (en)
EP (1) EP1336620A4 (en)
JP (1) JPWO2002042333A1 (en)
AU (1) AU2001290315A1 (en)
CA (1) CA2429467A1 (en)
WO (1) WO2002042333A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055336A2 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to cd84-like polypeptides and polynucleotides
US20040092712A1 (en) * 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
US7608684B2 (en) 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
CA2506580C (en) 2002-11-12 2010-08-17 Mochida Pharmaceutical Co., Ltd. Assay kit and antibody for human low molecular weight cd14
AU2004241069B2 (en) * 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
JP5118491B2 (en) * 2004-12-10 2013-01-16 ノビミューン エスアー Combination therapies targeting toll-like receptors and uses thereof
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
CN102898527B (en) 2011-07-25 2016-12-21 三星电子株式会社 Fusion protein, pharmaceutical composition and prevention or the method for the treatment of cancer
CN102940538B (en) * 2012-12-06 2014-10-15 吉林大学 Adjustable periodic mandibular protrusion pulling device
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3791188A1 (en) 2018-05-10 2021-03-17 The Methodist Hospital Methods for prognosis and management of disease
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115232211A (en) * 2019-11-19 2022-10-25 武汉全景生物技术有限公司 Novel anti-soluble CD14 subtype antibody and application thereof
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113939533B (en) * 2020-06-18 2022-12-06 武汉全景生物技术有限公司 Anti-soluble CD14 subtype antibody, kit and application thereof
EP4225796A1 (en) 2020-10-07 2023-08-16 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0485430T3 (en) 1989-08-01 1999-06-14 Scripps Research Inst Methods and compositions for improving symptoms of sepsis
AU695124B2 (en) 1993-05-28 1998-08-06 Scripps Research Institute, The Methods and compositions for inhibiting CD14 mediated cell activation
AU702604B2 (en) * 1994-05-12 1999-02-25 Quest International B.V. Process for inhibiting the growth of a culture of lactic acid bacteria, and optionally lysing the bacterial cells, and uses of the resulting lysed culture
EP0792162B1 (en) * 1994-09-16 2005-11-09 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
CA2208699A1 (en) * 1994-12-30 1996-07-11 Rockefeller University (The) Anti-inflammatory cd14 polypeptides
WO1998039438A1 (en) 1997-03-07 1998-09-11 Mochida Pharmaceutical Co., Ltd. Antisense compounds to cd14
US20040092712A1 (en) * 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor

Also Published As

Publication number Publication date
EP1336620A1 (en) 2003-08-20
EP1336620A4 (en) 2004-11-17
WO2002042333A1 (en) 2002-05-30
JPWO2002042333A1 (en) 2004-03-25
US7264967B2 (en) 2007-09-04
US20040091478A1 (en) 2004-05-13
CA2429467A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU2001290315A1 (en) Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
IL155340A0 (en) HUMANIZED ANTI LYMPHOTOXIN-beta-RECEPTOR ANTIBODIES
IL152389A0 (en) Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agents
IL156030A0 (en) Humanized antibodies
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
IL235116A0 (en) Antibodies to opgl
GB0029360D0 (en) Humanised antibodies and uses thereof
EP1391464A4 (en) Anti-cd40 monoclonal antibody
HUP0204074A3 (en) Humanized antibodies that sequester abetha peptide
EP1264885A4 (en) Antibody library
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
IL200608A0 (en) Methods for the detection of 193p1e1b protein and use of compositions containing a 193p1e1b protein or an antibody binding thereto
EP1399187A4 (en) Uses of monoclonal antibody 8h9
IL136459A0 (en) Antibody library
AU2001244711A1 (en) Tlr/cd14 binding inhibitor
AU2002216847A1 (en) Epitopes of pai-1
EP1455822A4 (en) Lyophilized monoclonal antibody compositions
AU2001267613A1 (en) Adjuvant composition comprising FHA protein or fragment of FHA protein in free form
EP1408112A4 (en) Monoclonal antibody binding to mt4-mmp catalytic domain
EP1393746A4 (en) Human polyclonal antibody compositions
AU2001267180A1 (en) Single-domain brain-targeting antibody fragments derived from llama antibodies
AU2002306373A1 (en) Monoclonal antibody binding to mt4-mmp catalytic domain
GB0029846D0 (en) Monoclonal antibody
GB0030139D0 (en) Monoclonal antibody